dennis mccain
  • Home
  • Investing
    • Dividend Kings
    • Div Aristocrats
    • Div Champions
    • Business Dev Cos
    • Monthly Dividends
  • Options
    • Weekly Options

Investing

Ideas and Strategies on Investing.

Previous Articles

Amgen

2/3/2016

1 Comment

 
AMGen (formerly Applied Molecular Genetics) is a multinational biopharmaceutical company headquartered in Thousand Oaks, California, and it is the largest independent biotechnology company in the world. Amgen's largest selling product lines are Neulasta and Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy, and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Nplate, Vectibux,  Sensipar/Mimpara, Prolia and XGEVA.
​
Picture

​Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Limited, UCB, Novartis AG, Bayer HealthCare Pharmaceuticals Inc., and Merck & Co. Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.
(Summary) (Company) (Chart)
2 February 2016
Price $150.11
1yr Target $185.00
Analysts 15
Dividend $4.00
Payout Ratio 47.78%

1yr Cap Gain 23.24%
Yield 2.66%

1yr Tot Return 25.90%
​
EPS (ttm) $8.37
EPS next yr $12.10
EPS next 5yr 9.53%
1yr Price Support $115.31
P/E 17.93
PEG 1.88
Beta 0.78
Market Cap $113.23 Bil
Revenues $21.46 Bil
Earnings $6.43 Bil

Profit Margin 29.96%
​
1yr EarnGR 54.92%
3
yr EarnGR 23.17%
5yr EarnGR 16.72%
1yr DivGR 21.53%
3yr DivGR 29.60%
5yr DivGR ---
Quick Ratio 5.10
Current Ratio 5.40
Debt/Equity 1.14
ROA 9.20%

ROE 23.90%
​
My Perspective
Picture
Amgen has been moving sideways in a very broad band since the middle of 2014. For swing traders, this has been an ideal platform for trading the stock. This is also the kind of situation that lends itself to option sellers. But it's not the best situation for those investors who have simply held the stock over all these years. 

But this stagnation has allowed the company to grow its fundamentals while the price of the stock remains range bound. This has allowed some of those fundamentals that were relatively high to come back within a range that makes the stock more desirable. 

With a P/E ratio under twenty, a dividend yield above two percent, and a payout ratio less than fifty percent, this stock is now on a list of stock I'll start to accumulate. This company will fit in nicely with my shares of Gilead Sciences and I expect these two companies to provide a growing dividend and a nice return on investment capital.

 

Picture
1 Comment
pengobatan sindrom nefrotik pada anak tanpa operasi link
9/19/2018 01:40:20 am

This article is very useful, thank you for sharing. And allow me to share articles too, it's about health and treatment. God willing

Reply



Leave a Reply.

    Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

    Picture

    Author

    I am an Individual Investor with specific interest in long term growth and then enhancing my returns with income from dividends and derivatives. I don't recommend stocks to anyone (it's a good way to lose friends) and no one reading this should misinterpret my blog as a recommendation for any type of investment. I am writing this solely for myself and my kids.


    RSS Feed


    Picture
    Top 100 Blogs for Dividend Investors

    Picture
    Follow Me on StockTwits!



    Dividend Growth Stocks
    Dividend Growth Investor


    Picture
    I'm on Seeking Alpha too!

    Archives

    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013


    ADDITIONAL RESOURCES:
    4 Month INDU Chart
    Dividend Ex-Dates
    Bidness Etc
    SharpCharts Voyeur
    StockCharts.com

    FINVIZ
    Seeking Alpha
    BDC Reporter
    Roadmap2Retire
    DivHut
    Dividend Growth Investor

    Dividend Yield

    Stock Market Mentor
    Chart Swing Trader
    Dividend Announcements
    IBD TV
    Stocks to Watch Today
    Dividend Detective

    DISCLAIMER
     I am not a licensed investment adviser, and I am not providing investment advise for you on this site. Please consult with an investment professional before you invest your money. Any opinion expressed here should not be treated as investment advice. I am not liable for any losses suffered by any party because of data or information published on this blog. Past performance is not a guarantee of future performance. Unless your investments are FDIC insured, they may decline in value.

    Picture
Powered by Create your own unique website with customizable templates.